EN
Home/United Kingdom/Blog/Can I switch from private to NHS Mounjaro?
UKUnited Kingdom NHS and access

Can I switch from private to NHS Mounjaro?

Paying privately and wondering if the NHS can take over? Here is what NHS rules say about moving across, and why weight already lost can count against you.

GLP Guidebook teamPublished 12 Oct 20265 min read15 sourcesWritten from published sources

Written for the UK.

The short answer

Only if you meet the NHS criteria when you switch, not the BMI you had before starting privately. In England that currently means a BMI of 35 or more (32.5 for some ethnic groups) and at least 4 of 5 named conditions. Being on it privately doesn’t move you up any queue, and practices can choose not to prescribe it.

Key takeaways

  • Cheshire and Merseyside ICB says people using Mounjaro privately may get an NHS prescription if they meet the NHS criteria at the point of transition.1
  • In England’s current phase, the NHS criteria are a BMI of 35 or more, or 32.5 for some ethnic groups, plus at least 4 of 5 named conditions.2
  • The same ICB says private patients “should not gain advantage over other patients waiting for NHS care”.1
  • NHS Mounjaro comes with a compulsory support programme; people who don’t want it can’t be prescribed Mounjaro on the NHS.1
  • GP practices in England don’t have to prescribe Mounjaro under the 2026/27 contract, so a switch depends on what your practice offers.1
Before you go further
  • GLP‑1 medicines are prescription-only medicines in the UK, never sold over the counter.3
  • Ozempic and Rybelsus are licensed for type 2 diabetes only, not for weight loss.4
  • A prescriber decides whether a medicine fits, which one and at what dose. Nothing here is a recommendation.
  • The risks are the same however you get it: see our side effects guide.
On this page
  1. What do NHS rules say about switching?
  2. Which BMI counts: before or after private treatment?
  3. Will my GP take over the prescription?
  4. What changes when you move to the NHS?
  5. What about Scotland, Wales and Northern Ireland?
  6. What if you don’t meet the NHS criteria?
  7. Questions people ask
  8. How we researched this
  9. Sources

What do NHS rules say about switching?

You can move to an NHS prescription only if you meet the NHS criteria at the time you switch, and you gain no priority.1

Cheshire and Merseyside ICB puts it plainly. People using tirzepatide “bought privately” may get it on the NHS. They must meet the criteria “at the point of transition”.1 But they “should not gain advantage over other patients waiting for NHS care”.1

NICE’s protection for people already on treatment covers tirzepatide “started in the NHS” before its guidance, not private treatment.2 We found no national NHS rule that treats private patients differently from anyone else.

Which BMI counts: before or after private treatment?

The ICB’s wording points to your measurements when you switch, so weight already lost privately can take you below the threshold.1

In England’s current phase, the NHS looks for a BMI of 35 or more. For South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds, it is 32.5. You also need at least 4 of 5 named conditions.2

Take someone 1.70 m (5 ft 7 in) tall who began at 104 kg (16 st 5 lb). Their BMI was 36. After losing 10%, they weigh 93.6 kg (14 st 10 lb), a BMI of 32.4. That is below 35, and below 32.5 too.

We found no published NHS rule that counts a starting BMI from a private record. The 5 conditions are high blood pressure, abnormal blood fats, sleep apnoea, heart or blood-vessel disease, and type 2 diabetes.2 They need to be on your record.

Will my GP take over the prescription?

Not automatically: in England each practice chooses whether to prescribe Mounjaro, and the NHS criteria apply whoever prescribed it before.1

Since 1 April 2026, Mounjaro prescribing in England sits in the GP contract. But “GP practices are not mandated to prescribe”.1 Cheshire and Merseyside ICB said it could not yet confirm which of its practices would prescribe.1

Whatever happens, the ICB says your GP should know you are taking Mounjaro, even privately. It may affect your health and other treatments.1 Our Mounjaro on the NHS post sets out each nation’s rules.

Free toolCould a GLP-1 be an option for you?

See what NICE and your nation’s NHS describe, in 2 minutes. It ends with questions for your GP.

Open the check

What changes when you move to the NHS?

You join a compulsory support programme, pay the NHS charge or nothing, and face a review if weight loss stalls.1,5,2

  • Support programme. Every NHS patient on Mounjaro for weight must take part in diet and activity support. If you don’t want that support, you can’t be prescribed it on the NHS.1
  • Cost. £9.90 per item in England, unless exempt; free in Scotland, Wales and Northern Ireland.5,6,7,8
  • Review. Under 5% lost after 6 months on the top tolerated dose means the prescriber decides whether to continue.2 See the NICE 5% rule.
  • Dose. The NHS prescriber decides the dose and how fast it rises.

Mounjaro’s UK list price rose in September 2025. Our cost post covers the numbers.9

What about Scotland, Wales and Northern Ireland?

Each nation has its own rules, and we found no published policy on private-to-NHS switching in any of them.

Scotland’s SMC accepted Mounjaro for adults with a BMI of 30 or more and a weight-related condition.10 Wales offers it in specialist services and to some urgent groups.11,12 Northern Ireland had no specialist weight service in May 2025.13

What if you don’t meet the NHS criteria?

You can carry on privately, or stop with your prescriber’s help; NICE says people stopping weight medicines should be offered support.14

Stopping often brings weight back. In the STEP 1 extension, people stopped all treatment after losing weight on Wegovy. Within a year, they regained about two-thirds of it.15 Our stopping post covers this.

NICE says to offer support to help maintain weight loss to people stopping weight medicines.14 Our stopping guide explains what to plan for.

Questions people ask

Do I have to stop private Mounjaro before seeing my GP?

We found no NHS rule saying you must. Cheshire and Merseyside ICB says it is important your GP knows you are taking it.1

Will the NHS use my BMI from before I started?

The ICB we read says you must meet the criteria at the point of transition. That points to your measurements at that time.1

Can I skip the NHS queue because I’m already on Mounjaro?

No. The ICB says private patients should not gain advantage over others waiting for NHS care.1

What if my GP practice doesn’t prescribe Mounjaro?

Practices in England can choose not to under the 2026/27 contract. Meeting the criteria doesn’t guarantee treatment.1

Is NHS Mounjaro free in Scotland, Wales and Northern Ireland?

NHS prescriptions are free in all three. In England the charge is £9.90 per item unless you are exempt.6,7,8,5

How we researched this

On 12 October 2026 we read NICE TA1026, one ICB’s patient page and the SMC decision. We also read the Welsh and Northern Ireland statements. NHS England’s commissioning page blocked our checks.

Only one ICB page we could open spelled out the switching rule, so we quote it by name. Other areas may word it differently.

Before you move on

  • Work out your BMI now, not when you started.
  • Check which of the 5 conditions are on your GP record.
  • Ask your practice whether it prescribes Mounjaro for weight.
  • Tell your GP you are taking it privately.
  • Plan what happens if you don’t meet the criteria.
Could it be an option?Already on a GLP‑1Stopping and the long term

More from the UK blog

UKUnited KingdomCan I get Mounjaro on the NHS in 2026? Who qualifies in England, Scotland, Wales and Northern IrelandUKUnited KingdomHow much do Mounjaro and Wegovy cost in the UK, on the NHS or privately?UKUnited KingdomWhat is the NICE 5% rule, and when does the NHS stop a weight-loss jab?
About GLP Guidebook

The monthly UK update

An independent guide to GLP‑1 medicines. We don’t sell medicines, take drug-company money, earn commissions or link to any provider. Once a month: NHS changes, approvals, list prices and safety alerts. How we write

Was this post easy to understand?

Sources

  1. NHS Cheshire and Merseyside (integrated care board). Tirzepatide (Mounjaro) for obesity: information for patients from 1 April 2026. Link
  2. NICE. Tirzepatide for managing overweight and obesity, technology appraisal TA1026, section 1 (recommendations and “What this means in practice”). Published 23 December 2024, last updated 1 September 2025. Link
  3. MHRA. UK first in Europe to authorise orforglipron for weight management and type 2 diabetes. Press release, 10 August 2026. Link
  4. MHRA. GLP-1 medicines for weight loss and diabetes: what you need to know. Guidance, published 5 June 2025, updated 5 February 2026. Link
  5. NHS Business Services Authority. NHS Prescription Prepayment Certificate (PPC). Link
  6. Scottish Government. Help with health costs (HCS2): quick guide; and Citizens Advice Scotland, Help with health costs. Link
  7. Welsh Government. Free prescriptions. Link
  8. nidirect (Northern Ireland government). Help with health costs. Link
  9. CNN (republished by ABC17 News). Eli Lilly hikes Mounjaro prices in the UK to make weight-loss drug cheaper in the US. 15 August 2025. Link
  10. Scottish Medicines Consortium. Tirzepatide (Mounjaro) for obesity, SMC2653: accepted for restricted use within NHSScotland. Link
  11. NICE. TA1026, section 4: Implementation (funding variation, 12-year period, 220,000 people, Wales). Link
  12. Welsh Government. People waiting for time-sensitive surgery get weight loss drugs on NHS. News release, 23 October 2025. Link
  13. Northern Ireland Assembly. Written ministerial statement, Department of Health: Establishment of a Regional Obesity Management Service for Northern Ireland. 21 May 2025. Link
  14. NICE. NG246, section on medicines and surgery (Table 1: when to stop treatment). Link
  15. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab 2022;24:1553–64. PMID 35441470. Link

Last checked 12 Oct 2026 · Next review due 12 Apr 2027 · Report an error

How this post was made. Written by the GLP Guidebook team from the sources above. It’s general information, not medical advice. Talk to your GP, pharmacist or prescriber before starting, stopping or changing any medicine. We don’t sell, prescribe or recommend any brand or provider. How we write